cardiovascular surgery
Conditions
Interventions
Control group:intravenous infusion of erythropoietin 500IU/kg 24 hours before surgery
Test group:Roxastat 50mg orally every other day before surgery
Sponsors
Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Age between 18 and 75 2. Cardiovascular surgery with cardiopulmonary bypass 3. Preoperative hemoglobin level (<130g/L for male, <120g/L for female) 4. Normal psychological state and agreed to participate in the study
Exclusion criteria
Exclusion criteria: 1. Age younger than 18 or elder than 75 2. Cardiovascular surgery without cardiopulmonary bypass 3. BMI10) 7. Emergent surgery 8. Patients who have already received Roxalstat or Recombinant human erythropoietin therapy 9. Coagulation disorders(Hereditary or acquired) 10. Allergic to any experimental medicine 11. Patients with malignant tumor, liver cirrhosis, thyroid dysfunction, respiratory failure and other diseases that significantly affect the clinical outcome 12. Patients who refused to participate in the trial or refused to sign an informed consent form
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Preoperative hemoglobin level;Perioperative incidence of major cardiovascular adverse events;Incidence of postoperative acute kidney injury; | — |
Secondary
| Measure | Time frame |
|---|---|
| Amount of blood used during operation;Amount of blood used after surgery;Postoperative 30-day mortality; | — |
Countries
China
Contacts
Public ContactZhou Qing
Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School
Outcome results
None listed